Molecular Weight(MW): 416.51
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
Purity & Quality Control
Choose Selective RAAS Inhibitors
|Description||Ramipril is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.|
|Features||A pro-drug converted to its active metabolite, ramiprilat, by liver esterase enzymes.|
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.  Ramipril enhances the activity of ACE-associated CK2 and the phosphorylation of ACE Ser1270 in cultured endothelial cells, but is unable to activate JNK or stimulate the nuclear accumulation of c-Jun in endothelial cells expressing a S1270A ACE mutant or in ACE-deficient cells. Prolonged Ramipril treatment increases ACE expression in primary cultures of human endothelial cells and in vivo (mouse lung), which can be prevented by pretreatment with the JNK inhibitor SP600125.  Ramipril displays little enhanced effect on the rate of in vitro endothelial apoptosis induced by the serum deprivation method. 
|In vivo||Chronic in vivo administration of Ramipril to rats at a dosage that has similar hypotensive effects in vitro HUVECs significantly reduces the rate of LPS-induced apoptosis compared to the other ACE inhibitors, which contrasts with the apoptosis effect in vitro.  Ramipril inhibits systolic blood pressure (SBP) with IC50 of 1.97 mg/kg in spontaneously hypertensive rats (SHR). When in combination with AT1-receptor blockade by candesartan-cilexetil increases SBP reduction synergistically rather than additively.  Administration of Ramipril to spontaneously hypertensive rats (SHR) produces significant inhibition of aorta ACE and lung ACE with IC50 ~5 mg/kg, but shows little effect for brain ACE ex vivo.  Ramipril prevents beta cell dysfunction in osteoprotegerin treated mice through decreasing islet monocyte/macrophage infiltration, fibrosis and apoptosis involving decreasing RAS, growth factor genes and inflammatory molecules expressions. |
-  Stevens BR, et al. Comp Biochem Physiol C, 1988, 91(2), 493-497.
-  Kohlstedt K, et al. Circ Res, 2004, 94(1), 60-67.
-  Ceconi C, et al. Cardiovasc Drugs Ther, 2007, 21(6), 423-429.
|In vitro||DMSO||83 mg/mL (199.27 mM)|
|Ethanol||83 mg/mL (199.27 mM)|
|In vivo||Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02924727||Recruiting||Acute Myocardial Infarction||Novartis Pharmaceuticals|Novartis||December 2016||Phase 3|
|NCT02632747||Recruiting||Diabetes Mellitus, Type 1||Boehringer Ingelheim|Eli Lilly and Company||May 2016||Phase 2|
|NCT02791958||Recruiting||Hypertension||Ferrer Internacional S.A.||March 2016||Phase 2|
|NCT02842424||Recruiting||Peripheral Arterial Disease||University of Nebraska||October 2015||Phase 4|
|NCT02499822||Recruiting||Hypertension|High Blood Pressure Variability||Istituto Auxologico Italiano|Bayer||October 2015||Phase 4|
|NCT02832973||Recruiting||Hypertension Resistant to Conventional Therapy||Sao Jose do Rio Preto University||September 2015||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.